For beclomethasone dipropionate when administered as part of a combined of the drug to its active metabolite beclomethasone-17-monopropionata and value of the maximum concentration plasma trenbolone side effects is slightly lower, while the absorption is faster than the monopreparation beclomethasone dipropionate.
for formoterol when administered as part of a combined plasma drug coincided with that of the single agent, but systemic activity was slightly higher than that of single agent.
No data obtained regarding pharmacokinetic or pharmacodynamic interactions between BDP and formoterol:
BDP under the action of esterase is converted to the active metabolite beclomethasone-17-monopropionat .
Inhaled rapidly absorbed light; intense absorption precedes its conversion its active metabolite beclomethasone-17-monopropionata . Systemic bioavailability provided by 36% due to light, and also due to the suction organs of the gastrointestinal tract ingested dose inhalation portion. The bioavailability of ingested is negligible, however, presystemic conversion causes that 41% BDP digested. There is almost a linear increase in systemic effects with increasing inhaled dose. The absolute bioavailability following inhalation is approximately 2% and 62% of the nominal dose in relation to the unmodified , respectively.
The connection to plasma proteins is high enough. Metabolism is characterized by a very high rate of clearance from the systemic circulation through the action of esterase present in most tissues. The main metabolitemetabolite . Less active metabolites are beclomethasone monopropionattrenbolone side effects and beclomethasone , which are also formed by metabolism, but their role in systemic exposure is very low.
Excretion main part excreted in feces as polar metabolites. Renal excretion of the and its metabolites is negligible. A special population Liver failure does not alter the pharmacokinetics and safety profile due to the fact that the latter is subjected to rapid metabolism The polar metabolites , and trenbolone side effects by the action of enzymes present in the gastro-intestinal tract, blood plasma, lung and liver. The pharmacokinetic properties of BDP in patients with renal failure has not been studied. Considering that both BDP and its metabolites in the urine almost not allocated, there is no reason to assume increased systemic action of the drug on the body of patients suffering from renal failure.
Formoterol Absorption and distribution of inhaled formoterol is absorbed into the lungs and gastrointestinal tract. Part inhalation dose that is swallowed, depending on the type of inhalation device and inhalation technique. So when using a metered dose inhaler multidose it can be up to 90%. Therefore swallowed fraction must be considered in the inhalation route of administration of the drug. At least 65% of an oral dose of formoterol is absorbed through the digestive tract, with 70% of this volume it undergoes first-pass metabolism. The maximum concentration of unchanged formoterol in plasma observed for 0.5. 1 hour after oral administration. Communication with plasma proteins of formoterol is from 61-64%, with the affinity to albumin – 34%. The trenbolone side effects range of therapeutic dosages affinity saturation is not observed.When perroralnom reception T1 / 2 is 2-3 hours. Inhalation 12-96 mcg of formoterol fumarate absorption of formoterol is linear. Metabolism Metabolism Formoterol is carried out, in particular, due to the direct conjugation fenolgidroksilnoy group.